Long-Term Ovarian Cancer Survival: What the Research Shows

Much of the conversation surrounding advanced-stage ovarian cancer understandably centers on treatment and recurrence. A new study looks further ahead, examining how mortality risk changes for patients who remain disease-free over time. Bram Goldstein, Ph.D., President and Senior Clinical Fellow of the Women’s Cancer Research Foundation, provides clinical context on findings that offer an encouraging view of long-term survival.

A Clinical Perspective of Long-Term Ovarian Cancer Survival from Bram Goldstein, Ph.D.

According to a new study in JCO Oncology Advances, patients with advanced-stage ovarian cancer who were disease-free for 7 years or more had nearly the same mortality risk as the general US population.

In this retrospective cohort study, researchers compared the mortality risk among long-term survivors, defined as patients who were disease-free for a specified time. The study included 2074 patients. The median age at diagnosis was 65 years, and more than 90% of patients had advanced-stage disease.

Most patients were treated with primary cytoreduction (debulking surgery) and received first-line systemic treatment with platinum and taxane chemotherapy. Overall, 113 patients achieved 10-year event-free survival (EFS).

Ovarian cancer was the main cause of death for patients at 2- and 5-year EFS. However, by 10 years event-free, the 5-year cumulative incidence of ovarian cancer-related death was similar to the rate of non-ovarian cancer-related death (8.2% vs. 6.3%).

This is the largest study to demonstrate that a subset of patients with advanced-stage ovarian cancer may have survival outcomes comparable with the general population.

Why This Research Matters

Ovarian cancer survival statistics often emphasize the first several years following diagnosis. This study helps broaden that picture by showing that mortality risk may continue to decline the longer a patient remains disease-free.

For patients and families, these findings offer a meaningful reason for hope. For researchers, they reinforce the importance of studying survivorship well beyond the first years following diagnosis.

Further reading: Mortality Risk Steadily Declines for Long-Term Ovarian Cancer Survivors — Cancer Therapy Advisor

Medical note: This article is intended for educational purposes only and does not provide medical advice, diagnosis, or individualized screening or treatment recommendations. Please consult a qualified healthcare professional about personal health concerns.